Anew Medical Inc

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anew Medical, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It operates through the following segments: Generic Drugs, Gene Therapy, and Pharmaceutical Programs. The Generic Drugs segment consists of portfolio of drugs and biosimilar biologics selling hard-to-source, difficult to find generic drugs and off-patent biologic therapies, and proprietary and patented technology platforms that include a library of melanocortin receptor-binding molecules. The Gene Therapy segment focuses on the gene therapy approach to introduce a therapeutic protein called “Klotho” inside the body to treat neurodegenerative diseases and other diseases of aging. The Pharmaceutical Programs segment includes treatments using small drug molecules that bind to the melanocortin receptors on human cells and affect skin pigmentation and other initiatives. The company was founded on August 2, 2004 and is headquartered in Omaha, NE.

Company will use novel, patented Klotho Gene (s-KL) in studies New York, NY, September 4, 2024 – PRISM MediaWire – ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development.

Healthy Longevity is One of Key Development Goals of ANEW's Novel Gene Therapy

Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 – ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors.

ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility

New York, NY. August 21, 2024 – ANEW MEDICAL, INC.

ANEW MEDICAL, INC. Acquires License to Needle-Free Dry Powder Autoinjector from Transfertech Sherbrooke (“TTS”)

New York, NY, August 19, 2024 – ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA) a U.S.

ANEW MEDICAL, INC. Appoints New CFO

Issuance of the Klotho gene-therapy patent will be instrumental in protecting ANEW's IP for development and commercialization in the U.S. New York, NY, August 15, 2024 – ANEW MEDICAL, INC. (“ANEW” or “the Company”) (NASDAQ: WENA), a U.S.

ANEW MEDICAL, INC. Strengthens Intellectual Property Protection with U.S. Patent Issuance for Its Secreted RNA Splice Variant of the Human Klotho Gene Used for the Treatment of Neurodegenerative and Age-Related Diseases

NEW YORK, NY, August 09, 2024 – ANEW MEDICAL, INC.

ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides

Color Star Technology Co Ltd

Conduit Pharmaceuticals Inc

Expion360 Inc

Premarket trading is some of my favorite trading to watch.

4 Stocks Moving Sharply Before the Market Opens

Anew Medical (NASDAQ: WENA ) stock is rising higher on Thursday alongside heavy pre-market trading of the biopharmaceutical company's shares. This has more than 15.9 million shares of WENA stock changing hands as of this writing.

Why Is Anew Medical (WENA) Stock Up 37% Today?

Patents issued in mainland China protect the Company's novel secreted Klotho protein and Its gene delivery system. Recent Patents issued in Hong Kong and Shanghai support protection to develop treatments for Alzheimer's Disease and other neurodegenerative diseases.

ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer's Disease and ALS

Anew Medical (NASDAQ: WENA ) stock is soaring higher on Tuesday after the biopharmaceutical company announced advancement plans for its patented Klotho gene therapy program. According to Anew Medical, it intends to advance this treatment for neurodegenerative disorders.

Why Is Anew Medical (WENA) Stock Up 51% Today?

Genomics data suggests having an active Klotho gene sequence may help people live longer, healthier lives The Company was granted patents in Europe, China, and Hong Kong and awaits issuance of patents in the U.S. and Canada NEW YORK, July 9, 2024 — ANEW MEDICAL, INC.

ANEW MEDICAL to Advance Patented Klotho Gene Therapy for Neurodegenerative Disorder Treatments

Collaboration focuses on research and development of ANEW's patented Klotho gene therapy in enhancing longevity and reducing age-related diseases ANEW's mission is to deliver transformative protein, cell, and gene therapies in areas of high unmet medical needs, particularly targeting highly prevalent neurodegenerative diseases and age-related disorders NEW YORK, June, 27. 2024 — ANEW MEDICAL, INC.

ANEW MEDICAL Forms Strategic Partnership with Japan's Okinawa Research Center for Longevity Science (ORCLS) to Study Klotho Gene

Anew Medical (NASDAQ: WENA ) stock is taking off on Wednesday after the biologic medicines company announced it has secured a key patent in Europe. This patent is connected to Anew Medical's secreted Klotho gene sequence and gene delivery systems.

Why Is Anew Medical (WENA) Stock Up 144% Today?

ANEW to explore therapeutics and specialty diagnostics utilizing the s-KL protein and will pursue other medical product development and commercial opportunities of interest Exclusive, worldwide intellectual property licensed from Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA) in Barcelona, Spain NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. (NASDAQ: WENA) (“ANEW” or “the Company”) a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders and specialty diagnostics, announces that is has been granted and issued a patent in Europe, EP3377091B1, for the use of ANEW's secreted Klotho gene sequence and gene delivery systems to be used in the treatment of diminished cognition, memory loss, dementia and other neurodegenerative diseases.

ANEW MEDICAL, INC. Secures Key Patent in Europe for Human Klotho Gene RNA Slice Variant and Protein

News for Anew Medical Inc Stock (WENA)